## The role of Endoscopic Ultrasound (EUS) in the management of patients with pancreatic cancer: now bigger than ever

Hiroyuki Isayama<sup>1</sup>, Yousuke Nakai<sup>1</sup>, Peter V. Draganov<sup>2</sup>

Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; <sup>2</sup>Division of Gastroenterology, Hepatology and Nutrition, University of Florida, Gainesville, Florida, USA

Corresponding to: Peter V. Draganov, MD, Professor of Medicine, Director of Endoscopy. Division of Gastroenterology, Hepatology and Nutrition, University of Florida, 1600 SW Archer Road, Room HD 602, PO Box 100214, Gainesville, FL 32610, USA. Email: Peter.Draganov@medicine.ufl.edu.



Submitted Jan 29, 2013. Accepted for publication Feb 26, 2013. doi: 10.3978/j.issn.2078-6891.2013.009

Scan to your mobile device or view this article at: http://www.thejgo.org/article/view/1065/html

In this issue of the Journal of Gastrointestinal Oncology De Angelis et al. provide a comprehensive review of the role of endoscopic ultrasound (EUS) in the management of pancreatic cancer. At present the two main established roles of EUS are imaging and tissue acquisition. In addition some EUS-guided therapies have gained limited but expanding role in pancreatic cancer patients.

As correctly pointed by the authors, the role of standard EUS imaging for diagnosis and staging has decreased with the advent of dynamic contrast enhanced multi-detector row computed tomography (MDCT). Nevertheless, contrary to the prevailing perceptions both EUS and MDCT are operator dependent and significant variability of image quality and interpretations exist with MDCT. Furthermore, EUS remains superior imaging modality to detect small pancreatic lesions, mural nodules within a cyst, small lymph nodes and coexisting biliary pathology. We concur with the authors that inmost patients EUS and MDCT should be considered complimentary rather than competing imaging modalities for the evaluation of patients with suspected pancreatic lesions with MDCT been the initial test in most patients. Anotable exception is the screening of populations at high risk for pancreatic cancer where the recent International Cancer of the Pancreas Screening (CAPS) Consortium summit endorsed EUS as the initial test of choice (1,2). EUS is also preferably used for serial surveillance of premalignant pancreatic lesions [e.g., Intraductal papillary mucinous neoplasm (IPMN)] without the radiation exposure associated with MDCT (3). The addition of contrast-enhanced EUS and elastography may expand the utility of EUS imaging for solid pancreatic masses but their role is yet to be determined (4,5). Furthermore, early data on EUS-guided needle based confocal laser endomicroscopy (nCLE) have shown promising results in the evaluation of pancreatic cysts (6,7).

On the contrary, EUS with fine needle aspiration (EUS-FNA) has refused to share the scene with other sampling modalities and has become the preferred method for tissue acquisition in patients with pancreatic lesions. EUS may not be necessary in all pancreatic cancer cases but pretreatment pathological diagnosis is essential in most patients with both resectable and advanced disease. Recently the role of EUS sampling has expanded further with the introduction of a new needle with core trap that can provide histologic samples also refereed as fine needle biopsy (EUS-FNB) (8). This is an exciting development because EUS-FNB can facilitate accurate tissue diagnosis in situations where FNA cytology has been known to be inadequate (e.g., autoimmune pancreatitis, lymphoma) but also can provide assessment for tumor vascular and lymphatic invasion. Furthermore, in the forceable future treatment decisions and patient prognosis most likely will be based on molecular markers and EUS appears to be the ideal tool to gather adequate tissue for analysis (9).

EUS has also has expanded its role in selected patients with pancreatic cancer as a valuable therapeutic tool. At present, EUS-guided fiducial placement is now routinely done to facilitate image guided radiation therapy (10), EUS-guided celiac plexus neurolysis can greatly facilitate the management of pancreatic cancer pain (11), and EUSguided biliary drainage is a viable alternative to percutaneous drainage in patient that had failed endoscopic retrograde cholangiopancreatography (ERCP) or in patients with altered gastric anatomy (12). Importantly, in the future EUS most likely will play an important role in delivering novel local antitumor therapy. Ethanol ablation for selected small mucinous cyst has shown promising results and EUS fine needle injection (EUS-FNI) of various viral and biologic therapies has undergone preliminary evaluation (13).

In conclusion, despite stiff competition from other

imaging modalities standard EUS imaging remains a valuable tool. Contrast-enhanced EUS, EUS elastography and needle based confocal endomicroscopy may further expand the utility of EUS imaging but their exact role is yet to be determined. EUS-FNA is currently the preferred modality for tissue acquisition in patients with pancreatic lesions and the advent of FNB may further solidify this essential role. The therapeutic role of EUS has expanded and ranges from primary in the case of fiducial deployment to fall back strategy in the case of EUS-guided biliary drainage. In the forceable future, EUS-FNI most likely will play a central role for delivery of novel targeted antitumor medications but for now its role is limited to palliative celiac plexus neurolysis.

## **Acknowledgements**

Disclosure: The authors declare no conflict of interest.

## References

- Canto MI, Harinck F, Hruban RH, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2013;62:339-47.
- Canto MI, Hruban RH, Fishman EK, et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 2012;142:796-804.
- Tanaka M, Fernández-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012;12:183-97.
- 4. Kitano M, Sakamoto H, Komaki T, et al. New techniques and future perspective of EUS for the differential diagnosis of pancreatic malignancies: contrast harmonic imaging. Dig Endosc 2011;23 Suppl 1:46-50.

Cite this article as: Isayama H, Nakai Y, Draganov PV. The role of Endoscopic Ultrasound (EUS) in the management of patients with pancreatic cancer: now bigger than ever. J Gastrointest Oncol 2013;4(2):121-122. doi: 10.3978/j.issn.2078-6891.2013.009

- Iglesias-Garcia J, Larino-Noia J, Abdulkader I, et al. EUS elastography for the characterization of solid pancreatic masses. Gastrointest Endosc 2009;70:1101-8.
- Nakai Y, Iwashita T, Park DH, et al. Diagnosis of Pancreatic Cysts: Endoscopic Ultrasound, Through-the-Needle Confocal Laser-Induced Endomicroscopy and Cystoscopy Trial (Detect Study). Gastrointest Endosc 2012;75:AB145-AB146.
- Nakai Y, Shinoura S, Ahluwalia A, et al. In vivo visualization of epidermal growth factor receptor and survivin expression in porcine pancreas using endoscopic ultrasound guided fine needle imaging with confocal laser-induced endomicroscopy. J Physiol Pharmacol 2012;63:577-80.
- Iglesias-Garcia J, Poley JW, Larghi A, et al. Feasibility and yield of a new EUS histology needle:results from a multicenter, pooled, cohort study. Gastrointest Endosc 2011;73:1189-96.
- 9. Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes revealaberrations in axon guidance pathway genes. Nature 2012;491:399-405.
- Chavalitdhamrong D, Ishmael A, Draganov PV. The Role of Fiducial Placement in the Treatment of Pancreatic Cancer: The Expanding Role of Endoscopic Ultrasound. Pancreatic Dis Ther 2012;2:e112.
- Arcidiacono PG, Calori G, Carrara S, et al. Celiac plexusblock for pancreatic cancer pain in adults. Cochrane Database Syst Rev 2011;(3):CD007519.
- 12. Chavalitdhamrong D, Draganov PV. Endoscopic ultrasound-guided biliarydrainage. World J Gastroenterol 2012;18:491-7.
- Herman JM, Wild AT, Wang H, et al. Randomized Phase III Multi-Institutional Study of TNFerade Biologic With Fluorouracil and Radiotherapy for Locally Advanced Pancreatic Cancer: Final Results. J Clin Oncol 2013;31:886-94.